ALZAI Health Corp. Secures Exclusive Global License for AI-Driven Liver Disease Risk Identification Technology

Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce that it has entered into an exclusive worldwide license agreement (the "Agreement") with MOR Research Applications Ltd. ("MOR"), the technology transfer company of Clalit Health Services and Yeda Research, the technology transfer company of the Weizmann Institute of Science and Development Co. Ltd. ("Yeda"), for proprietary artificial intelligence-driven liver disease risk identification technology (the "Licensed Technology").

Under the Agreement, ALZAI is granted an exclusive, worldwide, sublicensable license to develop, commercialize and sublicense the Licensed Technology. The Licensed Technology is intended to identify individuals at elevated risk of liver-associated diseases, including cirrhosis and other chronic liver conditions, using routine healthcare data.

The Licensed Technology is derived from proprietary algorithms and intellectual property developed by leading Israeli healthcare and academic institutions and is designed to support identification of individuals who may be at risk of liver disease before clinical diagnosis. ALZAI intends to integrate the Licensed Technology into its existing artificial intelligence platform and advance commercialization of the Licensed Technology through healthcare systems, life sciences organizations, pharmaceutical companies, and strategic commercial partners worldwide.

Under the terms of the Agreement, ALZAI will pay customary royalties to MOR and Yeda based on future commercialization revenues generated from products derived from the Licensed Technology, as well as a portion of revenues received through sublicensing arrangements. The Licensed Technology has been licensed on an exclusive basis within the field of liver-associated diseases and includes rights for ALZAI to further develop, commercialize, and sublicense the Licensed Technology globally.

Liver disease represents one of the fastest-growing healthcare challenges globally. Metabolic Dysfunction-Associated Steatotic Liver Disease ("MASLD"), formerly known as Non-Alcoholic Fatty Liver Disease, is estimated to affect more than one-third of the global adult population^[1], while millions of individuals remain undiagnosed until advanced stages of MASLD. Current diagnostic approaches often require specialized testing, imaging procedures, or specialist referrals, creating significant barriers to large-scale population screening.

Schreibe Deinen Kommentar